Korro Reports Encouraging RNA-Editing Results for KRRO-111, Targets Regulatory Submission in 2027

Key Points

• Korro Bio’s experimental KRRO-111 showed strong RNA-editing activity in laboratory and mouse studies for alpha-1 antitrypsin deficiency, or AATD.
• Repeat-dose mouse studies achieved up to 96% editing and increased total circulating AAT protein approximately sixfold compared with a control.
• In a separate mouse model, treatment reduced the harmful Z-AAT protein in the liver by 95%.
• The findings support further investigation of a treatment that could address both lung and liver disease.
• Korro expects a regulatory submission in the first half of 2027. Human safety and effectiveness have not been established.

Korro Bio (NASDAQ: KRRO) has reported preclinical findings for KRRO-111, an injectable RNA-editing treatment being developed for AATD.

The company’s goal is twofold: restore production of functional AAT protein while reducing the abnormal protein that accumulates in the liver. Korro described the results as potentially best-in-class, but the announcement does not establish superiority over other treatments.

Treatment Aims to Restore Useful Protein and Reduce Harmful Protein

KRRO-111 is designed to enter liver cells and use their existing RNA-editing machinery to correct the disease-associated SERPINA1 message.

The intended result is more functional M-AAT protein and less mutant Z-AAT. That combination could potentially address both the lung and liver effects of AATD, rather than replacing missing protein alone.

The treatment is administered under the skin and is being developed for repeat dosing.

Mouse Studies Show Strong Editing and Protein Changes

In repeat-dose studies in one mouse model, KRRO-111 achieved 96% RNA editing. Functional M-AAT made up 93% of circulating AAT, while total AAT levels reached approximately six times those in the control group at Day 57.

In a different mouse model, liver levels of harmful Z-AAT were 95% lower than in controls at Day 57.

Single-dose studies also showed editing and functional protein responses that remained detectable through at least Day 42. These findings demonstrate biological activity in the tested models—not proven improvements in human lung or liver health.

Regulatory Submission Is Expected in Early 2027

Korro expects to make a regulatory submission in the first half of 2027 as it works toward clinical development.

The announcement does not provide a human trial design, enrollment target or confirmed dosing date. A submission would be a step toward testing, not approval to sell the treatment.

Investor Takeaway: Promising Preclinical Profile, With Human Validation Still Ahead

For KRRO investors, the results strengthen the scientific rationale for a treatment designed to tackle both sides of AATD.

The next milestones are the regulatory submission, authorization to begin clinical testing and human results. The central question is whether the strong editing and protein changes seen in animals translate into a safe, durable and clinically meaningful benefit for patients.